Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (171-180 of 336) with videos related to

Pageof 34
Sort By:
Anticancer Research|October 3, 2018
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell CarcinomaMatteo Santoni, Francesco Piva, Ugo De Giorgi, et al.
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
Tumori|May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitorsRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneityMelissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
Expert Review of Cardiovascular Therapy|December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studiesMatteo Santoni, Alessandro Conti, Francesco Massari, et al.
Immunotherapy|February 1, 2019
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinomaMelissa Bersanelli, Letizia Gnetti, Elena Varotti, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLCPaola Bordi, Marzia Del Re, Roberta Minari, et al.
Immunotherapy|November 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, et al.
Immunotherapy|August 6, 2024
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapyFabiana Perrone, Federica Pecci, Michele Maffezzoli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pageof 34

Showing results (171-180 of 336) with videos related to

Sort By:
Pageof 34
Anticancer Research|October 3, 2018
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell CarcinomaMatteo Santoni, Francesco Piva, Ugo De Giorgi, et al.
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
Tumori|May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitorsRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneityMelissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
Expert Review of Cardiovascular Therapy|December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studiesMatteo Santoni, Alessandro Conti, Francesco Massari, et al.
Immunotherapy|February 1, 2019
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinomaMelissa Bersanelli, Letizia Gnetti, Elena Varotti, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLCPaola Bordi, Marzia Del Re, Roberta Minari, et al.
Immunotherapy|November 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, et al.
Immunotherapy|August 6, 2024
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapyFabiana Perrone, Federica Pecci, Michele Maffezzoli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pageof 34